Gates Foundation, Gilead and Others Drop $55 Million on Series B for Lyndra Therapeutics

Lyndra Therapeutics, based in Watertown, Mass., announced the closing of a Series B financing round worth $55 million. All original investors from the $23 million Series A round led by Polaris Partners were involved. New investors include HOPU Investments, Gilead Sciences, Invus, the Bill & Melinda Gates Foundation and Orient Life. The funds raised will be used to advance the company’s lead product into Phase II clinical trials, expand its Phase I pipeline.
Read more...

;